What the filings say
Gilead Sciences, Inc. (GILD) is listed in our Healthcare & pharma group. It filed 11 reports with the SEC in the past 30 days and 27 in the past 90 days. Its most recent earnings-related filing (8-K) was published on Oct 29. Over 90 days, Form 4 filings show no open-market insider buying and insider sales of about $39.5M. The latest 8-K (Oct 29) covered: Results of operations. 1 Schedule 13D/13G report appear in the recent filings.
How to read these filings. An 8-K is the fastest signal: item 2.02 carries earnings, 1.01 a material agreement, 5.02 executive or board changes, 3.02 an unregistered share sale and 5.07 shareholder vote results. A Form 4 shows trades by directors, officers and 10% owners; open-market purchases (code P) are rarer and more closely watched than sales, awards or tax withholding. Schedule 13D and 13G report holders above 5%, with 13D used when the holder may seek influence.
Numbers on this page are compiled automatically from SEC EDGAR. Dollar values of insider trades are the reported shares multiplied by the reported price and exclude derivative positions. Always open the original filing before acting on any figure.
Compiled from public SEC EDGAR data. Times are US Eastern. Titles link to the original filing on sec.gov. Information only — not investment advice. Updated: